Enhancing the Effects of Adolescent Alcohol Treatment With Atomoxetine

Inclusion Criteria: * Ages 14 to 20 years, inclusive * Self-reports consuming alcohol ≥ 2 days/week on average in the past 28 days * Meets the DSM-5 criteria for alcohol use disorder (AUD) * Interested in reducing alcohol use * Be able to verbalize an understanding of the consent/assent form, able to provide written informed consent/assent, verbalize willingness to complete study procedures, able to understand written and oral instructions in English, and able to complete the questionnaires required by the protocol. * If younger than 18 years, parent permissions is required. * Be able to take oral medication and be willing to adhere to the medication regimen * Complete all assessments required at screening and baseline * Provide contact information of someone, such as a parent or other family member, who may be able to contact the subject in case of a missed clinic appointment or follow-up assessment. * Be someone who in the opinion of the investigator would be expected to complete the study protocol * Agree to the schedule of visits, verbally acknowledge that s/he will be able to attend each scheduled visit, participate in phone visits and that s/he does not have any already scheduled events or a job that may substantially interfere with study participation. * Not anticipate any significant problems with transportation arrangements or available time to travel to the study site over the next 2 months. * Agree (if the subject is female and of child bearing potential) to use birth control Exclusion Criteria: * Currently receiving treatment for AUD * Significant alcohol withdrawal symptoms * Coexisting moderate to severe substance use disorder other than cannabis and nicotine * Urine toxicology screen positive drugs of abuse except for cannabis * Treated with pharmacotherapy for AUD or a carbonic anhydrase inhibitor in past 30 days * Compelled to alcohol treatment by the juvenile justice system or has probation or parole requirements that might interfere with study participation * History of liver disease or have clinically significant abnormal laboratory values * History of renal impairment or renal stones, narrow angle glaucoma or pheochromocytoma, heart problems or defects, abnormal blood pressure, progressive neurodegenerative disorder, or clinically significant neurological disorders * Clinically significant physical abnormalities per physical exam, hematological assessment, bilirubin concentration, or urinalysis * Pregnancy, nursing, or refusal to use reliable birth control, if female * Psychotropic medication use in the past 30 days * Current or lifetime diagnosis of psychotic disorders * Current bipolar disorder * Current major depressive episode * Ever attempted suicide * Current (past year) suicidality risk * Known sensitivity to atomoxetine * Be anyone who in the opinion of the investigator could not be safely withdrawn from alcohol without medical detoxification * Serious or unstable medical illness or any potentially life-threatening or progressive medical condition other than addiction that may compromise subject safety or study conduct * Abnormal calculated creatinine clearance defined as \< 80 mL/min * Evidence of cirrhosis of the liver (albumin \< 3.2 g/dL, or ascites by physical exam)